Dr. Michel J. Tremblay is a regular researcher in the field of infectious and immune diseases at the CHU Research Center of Québec-Laval University. He is also a Professor in the Department of Microbiology-Infectiology and Immunology of the School of Medicine at Laval University, and holds the Canada Research Chair in Human Immuno-Retrovirology.
He has been Vice-Dean, Research and Graduate Studies at the Faculty of Medicine, and is currently Assistant Vice-President, Research, Creation and Innovation at Laval University. Dr. Tremblay has published over 200 articles in peer-reviewed scientific journals, and to date has received nearly $ 15 million in funding as a principal investigator and just under $ 40 million in funding as co-researcher for his research projects. Dr. Tremblay has received several awards and distinctions, including the André Dupont Award from the Clinical Research Club of Quebec and the Léo-Pariseau Award from ACFAS. Dr. Tremblay is a member of the Canadian Research Consortium on HIV Healing (CanCURE) which is funded by the Canadian Institutes of Health Research (CIHR).
His research aims to deepen our knowledge of the pathogenesis of human immunodeficiency virus (HIV) infection, the etiologic agent of Acquired Immunodeficiency Syndrome (AIDS). His research focuses on several facets of HIV infection, such as the complex interactions that occur between HIV and certain target cells of the virus (e.g., macrophages, CD4 T cells, astrocytes, etc.) and large-scale analysis of gene expression patterns following viral infection, using DNA microarrays and RNA sequencing in combination with powerful bioinformatic tools.
2705, boulevard Laurier
R-2701.4
Québec, Québec
Canada G1V 4G2
- Barat, CorinneEmployeeCHUL+1 418-525-4444, extension 49333+1 418-654-2715corinne.barat@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-2701.6
Québec, Québec
Canada G1V 4G2 - Côté, CarolineEmployeeCHUL+1 418-525-4444, extension 48624+1 418-654-2715caroline.cote@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-2740
Québec, Québec
Canada G1V 4G2 - Hany, LaurentEmployeeCHUL+1 418-525-4444, extension 48624laurent.hany.1@ulaval.caLaurent.Hany@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-2740
Québec, Québec
Canada G1V 4G2
The delicate balance between neurotoxicity and neuroprotection in the context of HIV-1 infection
Journal ArticleGlia, 69 (2), 2021.
Author Correction: Role of RIPK1 in SMAC mimetics-induced apoptosis in primary human HIV-infected macrophages
Journal ArticleSci Rep, 11 (1), 2021.
Role of RIPK1 in SMAC mimetics-induced apoptosis in primary human HIV-infected macrophages
Journal ArticleSci Rep, 11 (1), 2021.
HIV-1 infection and latency-reversing agents bryostatin-1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes
Journal ArticleGlia, 68 (11), 2020.
Host mRNA decay proteins influence HIV-1 replication and viral gene expression in primary monocyte-derived macrophages
Journal ArticleRetrovirology, 16 (1), 2019.
Expression of MDM2 in Macrophages Promotes the Early Postentry Steps of HIV-1 Infection through Inhibition of p53
Journal ArticleJ Virol, 93 (7), 2019.
Medroxyprogesterone acetate alters the vaginal microbiota and microenvironment in women and increases susceptibility to HIV-1 in humanized mice
Journal ArticleDis Model Mech, 12 (10), 2019.
Interferon-β induced in female genital epithelium by HIV-1 glycoprotein 120 via Toll-like-receptor 2 pathway acts to protect the mucosal barrier
Journal ArticleCell Mol Immunol, 16 (2), 2019.
A new tool for detection of extracellular traps
Journal ArticleMethods Appl Fluoresc, 6 (3), 2018.
SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition
Journal ArticlemBio, 9 (3), 2018.
Active projects
- Canadian HIV Cure Enterprise 2.0: Targeting the interplay between myeloid cells and C04+ T-cells for HIV cure, from 2019-04-01 to 2025-03-31
- Microglia as a viral reservoir for HIV-1 in the human brain and its role in neuroinflammation, from 2021-04-01 to 2026-03-31
Recently finished projects
- Contribution - consortium Érudit, from 2022-01-01 to 2024-04-30
- Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2024-03-31